Researchers and people living with hepatitis B meet in Paris at the third Hepatitis B Community Forum <<Click here>>

Welcome to Hepatitis Delta Connect!

A dedicated program of the Hepatitis B Foundation to increase awareness about hepatitis delta - a serious virus that coinfects hepatitis B patients - and to promote screening and testing, and provide information and support for those affected. 

Copy of Website transmission graphic asian african blended

    Clinical Trial Finder - Find A Clinical Trial Near You! 

          hepbfoundation hepdelta banner 2            

Join HBF and the National Viral Hepatitis Roundtable for an Upcoming Webinar Series!

Join NVHR and Hepatitis B Foundation for a two-part webinar series focused on drug development and the clinical trial process for current hepatitis B and hepatitis D therapies!

Demystify 10.5 Square 1

PART ONE: Demystifying Drug Development: From Molecule to Medicine

This webinar will provide an overview of the clinical trial process, current HBV and HDV therapies, and an introduction to interpreting clinical trial data. This webinar is part ONE of a two-part series intended for patients, advocates, and other stakeholders who are interested in learning more about the clinical trial process for HBV and HDV. 

WHEN: Wednesday, October 5, 2:00PM ET

Click here to register for Part 1!

Trials 11.19 Square 1

PART TWO: Drug Trials and Tribulations: Reflections on Equity and Access

This webinar will discuss the HBV and HDV clinical trial experience as it relates to access and equity. This webinar is part TWO of a two-part series intended for patients, advocates, and other stakeholders who are interested in learning more about the clinical trial process for HBV and HDV. 

WHEN: Wednesday, October 19, 2:00PM ET

Click here to register for Part 2!

Check Out Our Latest Webinar!

Recordings Available FBIG

In Case You Missed It... Catch the recording of "The Lived Experience of Hepatitis Delta" webinar here!

Hear real-world HDV perspectives from people around the globe who have been personally affected by hepatitis delta. The featured speakers are Basu Lkhagvasuren, Ibrahima Gueye, Danielle Raphael and, Lori Scott. They share insights about their experiences, and will speak specifically to their navigation of hepatitis delta diagnosis, treatment, and management, and the effects that the virus has had on their lives.

Hep Delta Patient and Provider Surveys FB IG

We would love to hear from you! Complete the survey to sign upPlease note: This survey link is specifically for those living with hepatitis delta, or those who are caretakers of people living with hepatitis delta.

Hep Delta Patient and Provider Surveys FB IG 3

Take our brief survey & sign up to receive updates on clinical trials, info about hepatitis delta monitoring, management & care + more! Sign up today! Please note: This survey link is specifically for healthcare providers caring for people living with hepatitis delta.

Am i at risk
Newly Diagnosed png

Website map by users2

We've educated 13,000 people in 111 countries!

 

News & Updates

May 2022 Blog Post: Roundtable Discussion Highlights Hepatitis Delta

February 2022 Blog Post: 2022 - The Year of Hepatitis Delta

March 2021 Blog Post: Hepatitis B and Hepatitis Delta

January 2021 Blog Post: Eiger Presents Clinical Trial Results at The Liver Meeting Digital Experience™ 2020

September 2020 Blog Post: New Hepatitis Delta Treatment Approved by European Commission

May 2020 Blog Post: Does Hepatitis Delta Increase My Risk for Liver Cancer?

View our webinar, Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies? recording here.

09/2022: Replicor Inc. has updated clinical data on the compassionate use program for treating chronic HBV/HDV co-infection in cirrhotic patients
09/2022: Diagnosing and Screening for Hepatitis D Viral Infection
06/27/22: Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2022
06/27/22: Vir Biotechnology Inc. Announces New Clinical Data from Its Broad Hepatitis B Program
06/23/22: Treatment with Hepcludex (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
06/16/22: Review Shines a Light on the Overlooked Virus, Hepatitis D
06/08/22: Eiger BioPharma Announces Multiple Presentations at EASL's International Liver Congress 2022
04/27/2022: Vir Biotechnology Unveils New Plans for Hepatitis D Treatment
03/23/2022: New Hepatitis D Central Resource Available from Healio
02/22/2022: We Should Be Screening Now for HDV with Emerging Drug Therapies in Phase 3
02/17/2022: Four Questions with Professor Maria Buti: Understanding Hepatitis D
02/11/2022: New Hepatitis Delta Podcast Episode: Viral Hepatitis: On the Road to Elimination
02/04/2022: Patient Perspective: Living with HBV and HDV Coinfection in Pandemic Times
01/20/2022: Hepatitis D Changing Context Global Prevalence
01/04/2022: New Slideset Updated on Don't Delay with Delta: Best Practices and Calls to Action in HDV
12/21/2021: Bulevirtide Improves Quality of Life in Chronic HDV
12/21/2021: Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection
12/20/2021: Medical Minutes Podcasts on HDV Epidemiology and Universal Screening
12/18/2021: Large Proportion of Undiagnosed Anti-HDV Positive Individuals Due to Lack of Testing
12/16/2021: UN Adopts Resolution on Rare Diseases
12/13/2021: Bulevirtide Shows Real-World Efficacy Versus HDV
12/03/2021: Should We Screen All Patients with Hepatitis B for Hepatitis Delta?
12/01/2021: Hepatitis Delta Presentations from the 2021 AASLD Liver Meeting Now Available
12/01/2021: Ethnic Variations in Clinical Presentation and Treatment Eligibility for HDV Infection at a US Referral Center
11/19/2021: Gilead Files BLA for Bulevirtide to Treat Chronic HDV Infection
11/12/2021: Prevalence and Characteristics of Hepatitis Delta in the United States: An Analysis of All-Payer Claims Databases
09/29/2021: The Kinesin KIF4 Mediates HBV/HDV Entry Through Regulation of Surface NTCP Localization and Can Be Targeted by RXR Agonists in vitro
08/24/2021: The Highly Complementary Model of Hepatitis D and Hepatitis B, Described by Scientists, Can Broadly Cover the HDV Replication Cycle
07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030
07/27/2021: Risk of Hepatocellular Carcinoma in Hepatitis B & D Virus Co-Infected Patients: A Systematic Review and Meta-Analysis of Longitudinal Studies
07/12/2021: Significant Disruptions in the International Incidence of Hepatitis Delta Virus
Get Connected

square facebook 512Twitter icon horizontal2instagram icon

Contact us button2